What Corporate Venture Funds Get Wrong about Strategic Value
Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact.
Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures.
Outro Raises $7M To Support Safe Deprescribing
Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures.
Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem
Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make.
Loneliness And Diabetes: Harnessing an Opportunity for Better Outcomes
Asking the right questions about community support, caregiving responsibilities, emotional well-being, and the availability of trusted social networks can establish important context for a person’s outcomes — and spark conversations about social needs that might never otherwise take place.